Asthmanex is a brand name for the anti-inflammatory agent mometasone furoate, a corticosteroid used in various formulations (inhaler, intranasal spray or topical ointment) for the treatment of asthma and allergic rhinitis as well as inflammatory skin disorders such as eczema and psoriasis.
A prescription inhalant drug marketed by Schering-Plough, Asthmanex – which is available as a “twisthaler” – is approved for the maintenance treatment of asthma in patients four years of age and older. A dosage of 110mcg is approved for patients age four to 11, while a dosage of 220mcg is approved for patients age 12 and older. Asthmanex is not indicated for the rescue treatment of sudden, severe asthma symptoms.
At PatientsLikeMe, where more than 120,000 patients are sharing their experiences with conditions, symptoms, treatments and more, three patients report using Asthmanex while 27 patients report using a formulation of mometasone. What can we learn from these patients’ experiences? Quite a bit, actually, thanks to PatientsLikeMe’s unique data-sharing platform. For example, the most commonly reported mometasone duration amongst current users is two years or more, while the top reasons for discontinuing the mediation include doctors’ advice, expense and “it did not seem to work.”
Wondering about side effects? Only one patient ranked the side effects as “mild,” while zero patients reported having “moderate” or “severe” side effects. Check out the three treatment evaluations of Asthmanex and eight treatment evaluations of mometasone submitted by our patients to gain even more insight.
JOIN PATIENTSLIKEME TODAY
Have you taken Asthmanex – or another form of mometasone? Join PatientsLikeMe and add your experiences to our growing body of knowledge. Then, stay to exchange advice and support, research common treatments and learn from other patients like you.